BrainGate Neural Interface for Tetraplegia
(BG-Tablet-01 Trial)
Trial Summary
What is the purpose of this trial?
People with brainstem stroke, advanced amyotrophic lateral sclerosis (ALS, also known as Lou Gehrig's disease), or other disorders can become unable to move or speak despite being awake and alert. In this project, the investigators seek to further translate knowledge about interpreting brain signals related to movement, and to further develop an intracortical brain-computer interface (iBCI) that could restore rapid and intuitive use of communication apps on tablet computers by people with paralysis.
Will I have to stop taking my current medications?
The trial does not specify if you need to stop taking your current medications, but it excludes those on chronic steroids or immunosuppressive therapy. It's best to discuss your specific medications with the trial team.
What data supports the effectiveness of the BrainGate Neural Interface System treatment for tetraplegia?
Is the BrainGate Neural Interface System safe for humans?
The BrainGate feasibility study, which is the largest and longest-running clinical trial of an implanted brain-computer interface, provides safety data for the BrainGate Neural Interface System. While the study focuses on people with paralysis, it offers valuable insights into the safety of chronically implanted microelectrode arrays in humans.23678
How is the BrainGate Neural Interface System treatment different from other treatments for tetraplegia?
The BrainGate Neural Interface System is unique because it uses a small, implanted device in the brain to directly translate neural activity into control signals for assistive technologies, allowing people with tetraplegia to control devices like computers and tablets with their thoughts. This approach differs from other treatments as it provides a direct brain-computer interface, enabling more natural and precise control over technology without relying on muscle movement.14567
Eligibility Criteria
This trial is for individuals with severe paralysis due to conditions like brainstem stroke, ALS (Lou Gehrig's Disease), or spinal cord injuries leading to quadriplegia. Participants should be unable to move or speak but remain alert. Specific inclusion and exclusion criteria details are not provided.Inclusion Criteria
Exclusion Criteria
Trial Timeline
Screening
Participants are screened for eligibility to participate in the trial
Implantation and Initial Testing
Participants undergo implantation of the BrainGate Neural Interface System and initial testing of the device
Long-term Evaluation
Participants are monitored for safety and effectiveness of the BrainGate Neural Interface System over a one-year period
Follow-up
Participants are monitored for safety and effectiveness after the main evaluation period
Treatment Details
Interventions
- BrainGate Neural Interface System (Brain-Computer Interface)
BrainGate Neural Interface System is already approved in United States for the following indications:
- Tetraplegia
- Spinal cord injury
- Brainstem stroke
- ALS